Key result
Hyperuricemia linked to ~67% higher all-cause mortality in men and increased risk in women.
Why the study?
Findings on how serum uric acid impacts age-related outcomes differ between sexes, and predictive data on all-cause mortality remain limited, particularly in the Japanese population.
Is hyperuricemia associated with increased all-cause mortality in Japanese community-dwelling males and females?
Cohort (n=3,553)
Is hyperuricemia associated with increased all-cause mortality in Japanese community-dwelling males and females?
Effect estimate: HR 1.67 (males), HR 2.17 (females) (95% CI 1.06-2.63 (males), 1.20-3.94 (females))
Hyperuricemia is a significant independent risk factor for all-cause mortality in both male and female Japanese community-dwelling individuals.
Hyperuricemia may flag higher mortality risk in Japanese adults; leaves open causal role and need for interventional trials.
Serum uric acid (SUA) is a key determinant of cardiovascular diseases (CVDs). Studies have also shown that SUA independently impacts age-related health outcomes, although their findings differ between males and females. Furthermore, predictive data on all-cause mortality remain limited, particularly for the Japanese population. Thus, this study examined the association between SUA and survival prognosis among males and females based on a follow-up period of 7 or 19 years. The study was based on 1,573 male (63 ± 14 years) and 1,980 female (65 ± 12 years) participants who participated in a Nomura Cohort Study in 2002 (Cohort 1) and 2014 (Cohort 2), and continued throughout the follow-up period. A basic resident register was referenced to derive the adjusted relative risk estimates for all-cause mortality. Finally, a Cox proportional hazards model analysis was conducted and was adjusted for possible confounders to estimate hazard ratios (HRs). 95% confidence intervals (CIs) were computed separately for male and female participants. Of the total 3,553 participants, 905 (25.5%) were deceased. Of these, 473 were male (30.1% of all males) and 432 were female (21.8% of all females). Hyperuricemia was defined in males with SUA levels of 8.5 mg/dL or higher, and in females with SUA levels of 7.5 mg/dL or higher, and was associated with a significantly increased HR for all-cause mortality (males: 1.67; 95% CI: 1.06–2.63; females: 2.17; 95% CI: 1.20–3.94). The data were further stratified based on age (< 65 years or ≥ 65 years), body mass index (BMI) (< 25.0 kg/m2 or ≥ 25.0 kg/m2), History of cardiovascular disease, estimated glomerular filtration rate (< 60 mL/min/1.73 m2 or ≥ 60 mL/min/1.73 m2), and presence of SUA-lowering medication. All stratified groups demonstrated a similar trend. The hyperuricemia group in particular reported a significant increase in HR. On the other hand, a U-shaped increase in HR was observed in those with BMI greater than 25 kg/m2 and SUA-lowering medication, but interaction effect was not significant. Hyperuricemia is a key risk indicator for all-cause mortality in male and female community-dwelling individuals in Japan.
No takes yet. Share an insight, caveat, or question.
Kikuchi et al. (2022) conducted a cohort in Community-dwelling individuals (n=3,553). Hyperuricemia vs. Normal serum uric acid levels was evaluated on All-cause mortality (HR 1.67 (males), HR 2.17 (females), 95% CI 1.06-2.63 (males), 1.20-3.94 (females)). Hyperuricemia was associated with a significantly increased risk of all-cause mortality in both male (HR 1.67; 95% CI 1.06-2.63) and female (HR 2.17; 95% CI 1.20-3.94) community-dwelling individuals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: